Ken Griffin
CRDL

Ken Griffin’s Cardiol Therapeutics CRDL Stock Holding History

Ken Griffin’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11M Buy
+819,904
New +$841K ﹤0.01% 7440
2025
Q4 		– Sell
-463,462
Closed -$485K – 12828
2025
Q3 		$496K Buy
+463,462
New +$562K ﹤0.01% 9162
2025
Q1 		– Sell
-38,110
Closed -$46.8K – 14617
2024
Q4 		$48.8K Buy
38,110
+31,889
+513% +$53.8K ﹤0.01% 12417
2024
Q3 		$12.3K Sell
6,221
-19,966
-76% -$41.4K ﹤0.01% 13112
2024
Q2 		$52.9K Sell
26,187
-34,211
-57% -$72.6K ﹤0.01% 11692
2024
Q1 		$109K Buy
+60,398
New +$81.4K ﹤0.01% 11228
2023
Q3 		– Sell
-17,743
Closed -$15.8K – 14385
2023
Q2 		$15.8K Sell
17,743
-973
-5% -$642 ﹤0.01% 12924
2023
Q1 		$9.12K Buy
+18,716
New +$11.1K ﹤0.01% 13606
2022
Q4 		– Sell
-46,204
Closed -$28.2K – 14927
2022
Q3 		$48K Buy
46,204
+22,313
+93% +$27.2K ﹤0.01% 11660
2022
Q2 		$32K Sell
23,891
-4,561
-16% -$6.49K ﹤0.01% 12181
2022
Q1 		$44K Sell
28,452
-148,617
-84% -$245K ﹤0.01% 12878
2021
Q4 		$328K Buy
+177,069
New +$489K ﹤0.01% 10727

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ken Griffin's CRDL Position: Q1 2026 in Review

Ken Griffin opened a new position in Cardiol Therapeutics (CRDL) in Q1 2026: 819,904 shares worth $1.11M. The stake represents ﹤0.01% of the portfolio and ranks #7440 among its holdings. This is a return to the name: Ken Griffin previously reported a position in CRDL as recently as Q3 2025.

Ken Griffin first reported a position in CRDL in Q4 2021 and has held it in 12 quarters since. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Ken Griffin held 819,904 shares of Cardiol Therapeutics worth $1.11M as of Q1 2026.
  • Cardiol Therapeutics was a new Ken Griffin position in Q1 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #7440 holding.
  • Ken Griffin first reported a position in Cardiol Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.